Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milvexian. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 known ✓ | P03951 | 20/20 | 0.91 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.91 |
| ▸ | F2 | P00734 | 1/20 | 0.91 |
| ▸ | PLG | P00747 | 1/20 | 0.91 |
| ▸ | PLAU | P00749 | 1/20 | 0.91 |
| ▸ | PLAT | P00750 | 1/20 | 0.91 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.91 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.91 |
| ▸ | F7 | P08709 | 1/20 | 0.91 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.91 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.91 |
| ▸ | CTRL | P40313 | 1/20 | 0.91 |
| ▸ | CTRB2 | Q6GPI1 | 1/20 | 0.91 |
| ▸ | CTRC | Q99895 | 1/20 | 0.91 |
| ▸ | KLK1 | P06870 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milvexian SCHEMBL16971760 | 1.00 | F11 (0.91) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29491953 | 1.00 | F11 (0.91) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16972161 | 1.00 | F11 (0.91) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29491830 | 0.95 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29372568 | 0.95 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29392086 | 0.95 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982794 | 0.95 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982996 | 0.95 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982989 | 0.95 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982998 | 0.95 | F11 (1.00) | F11KLKB1F2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4286372-A2 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-12-06 | — | — | EP | claimed |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4286372-A3 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4286372-A2 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4286372-A2 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-116987080-A | Macrocyclic compounds with heterocyclic P2' groups as factor XIA inhibitors | 百时美施贵宝公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-3828186-B1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-110845498-B | Macrocyclic compounds having heterocyclic P2' groups as factor XIA inhibitors | 百时美施贵宝公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-3988549-A1 | MACROCYCLES WITH HETEROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F2 | F11 4/4885KLKB1 7/4885F2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.